

Reimbursement Coding Options for Independent Clinics

QUZYTIR® (cetirizine hydrochloride injection), 10 mg/mL, for intravenous use

Disclaimer: It is important to note that the codes identified below are examples only. Each provider is responsible for ensuring all coding is accurate and documented in the medical record based on the condition of the patient. The use of the following codes does not guarantee reimbursement. The ultimate responsibility for obtaining reimbursement lies with the physician, provider, or patient. Please consult with your reimbursement specialist for any practice-specific reimbursement or billing questions.

National Drug Code (NDC)

The NDC is a universal product identifier comprised of a 3-segment number that identifies drugs by manufacturer, dosage, and package size. Payers may require the submission of an 11-digit NDC on healthcare forms, and electronic claims may be denied for drugs billed without a valid 11-digit NDC. Contact your patient's health plan to determine claim submission requirements and to determine accurate reporting of NDC codes.

Dosage ¹	11 Digit Code ¹
Carton containing 25 single-use vials (10 mg/mL cetirizine hydrochloride)	70720-0100-25
Carton containing 1 single-use vial (10 mg/mL cetirizine hydrochloride)	70720-0100-10

Current Procedural Terminology (CPT)

Submitting accurate codes and claims is important to ensure proper reimbursement of services. The chart below lists potential CPT codes for your reference when submitting claims for your patients who receive QUZYTIR.

Code	Description
96374	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug.
96375	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (list separately in addition to code for primary procedure).
96376	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (list separately in addition to code for primary procedure).

Healthcare Common Procedure Coding System (HCPCS)

Submitting accurate codes and claims is important to ensure proper reimbursement of services. The chart below lists a potential code for your reference when submitting claims for your patients who receive QUZYTIR.

Code ²	Description ²
J1201	Injection, cetirizine hydrochloride, 0.5mg

Additional Information on J-code Billing:

- A CMS 1500 form is often required; please enter the following information in box 19 or box 24:
 - o Drug name
 - o Strength
 - o Dosage of the drug
 - o Number of billable units at 0.5mg (2.5mg dose = 5 billable units, 5mg dose = 10 billable units, or 10mg dose = 20 billable units, based on age and indication)
- J1201 is billed per 0.5mg
- Check with your individual payer for specific requirements
- Recommended dosages:
 - o Adults and adolescents 12 years of age and older: 10 mg
 - o Children 6 to 11 years: 5 mg or 10 mg
 - o Children 6 months to 5 years: 2.5 mg
- Recommended dosage regimen is once every 24 hours as needed for acute urticaria

Special Notes:

According to the Medicare Claims Processing Manual, chapter 17, section 40, "Discarded Drugs and Biologicals," if a physician must discard the remainder of a vial after administering a dose to a Medicare patient, the program covers the amount discarded along with the amount administered. The coverage of discarded drugs applies only to single-use vials.³ For drug amounts discarded/not administered to the patient, Centers for Medicare & Medicaid Services states that Medicare contractors may require the use of modifier J. Modifier JW is used to identify unused drugs or biologics from single-use vials or single-use packages that are appropriately discarded. Modifier JZ is used to attest that no amount of drug was discarded and eligible for payment.⁴

Quzyttir®
Cetirizine HCl Injection
10 mg/mL

Diagnosis Code (ICD-10)

Submitting accurate codes and claims is important to ensure proper reimbursement of services. The chart below lists potential diagnosis codes for your reference when submitting claims for your patients who receive QUZYTIR® (cetirizine hydrochloride injection), for intravenous use.

Code ⁵	Description ⁵	Code ⁵	Description ⁵
L50	Urticaria	L50.4	Vibratory urticaria
L50.0	Allergic urticaria	L50.5	Cholinergic urticaria
L50.1	Idiopathic urticaria	L50.6	Contact urticaria
L50.2	Urticaria due to cold and heat	L50.8	Other urticaria
L50.3	Dermatographic urticaria	L50.9	Urticaria, unspecified



Questions? Call 1-855-686-8725 | Mon-Fri 9:00am–6:00pm EST

Indication and Important Safety Information

INDICATION AND USAGE

QUZYTIR is indicated for the treatment of acute urticaria in adults and children 6 months of age and older.

Limitations of Use: QUZYTIR is not recommended in pediatric patients <6 years of age with impaired renal or hepatic function.

IMPORTANT SAFETY INFORMATION

Contraindications: Known hypersensitivity to QUZYTIR or any of its ingredients, to levocetirizine, or hydroxyzine.

Warnings and Precautions: The occurrence of somnolence/sedation has been reported in some patients. Advise patients to exercise due caution when driving, or when operating potentially dangerous machinery. Avoid concurrent use of QUZYTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur.

Adverse Reactions: The most common adverse reactions (incidence <1%) with QUZYTIR are dysgeusia, headache, paresthesia, presyncope, dyspepsia, feeling hot, and hyperhidrosis.

The most common adverse reactions (incidence ≥2%) with chronic dosing of oral cetirizine hydrochloride in adults are somnolence, fatigue, dry mouth, pharyngitis, and dizziness. Adverse reactions observed in pediatric patients with chronic use of oral cetirizine hydrochloride are headache, pharyngitis, abdominal pain, coughing, somnolence, diarrhea, epistaxis, bronchospasm, nausea, and vomiting.

To report suspected adverse reactions, contact the FDA at 1-800-FDA-1088 or www.FDA.gov/medwatch. You may also contact TerSera Therapeutics at 1-844-334-4035 or medicalinformation@tersera.com.

Please see [Full Prescribing Information](#).

References:

- QUZYTIR (cetirizine hydrochloride injection). Prescribing Information. TerSera Therapeutics LLC.
- Centers for Medicaid & Medicaid Services. Medicare Claims Processing Manual, Chapter 17, Section 40 (February 15, 2024). Accessed May 21, 2024. <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c17.pdf>.
- Centers for Medicare and Medicaid Services. July 2024 Alpha-numeric HCPCS File at <https://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system/quarterly-update>. Accessed on May 22, 2024.
- Centers for Medicare & Medicaid Services. Medicare Program: Discarded Drugs and Biologicals - JW Modifier and JZ Modifier Policy Frequently Asked Questions. Accessed May 21, 2024. <https://www.cms.gov/medicare/medicare-fee-for-service-payment/hospitaloutpatientpps/downloads/jw-modifier-faqs.pdf>.
- Centers for Disease Control and Prevention. ICD-10 Lookup Tool. April 2024. Search Term: urticaria. <https://icd10cmtool.cdc.gov/?fy=FY2024&query=urticaria>. Accessed on June 2, 2024.